Cyclophosphamide

[1]Schwartz PS, et al. Cyclophosphamide induces caspase 9-dependent apoptosis in 9L tumor cells. Mol Pharmacol. 2001 Dec;60 (6) :1268-1279.|[2]al-Jafari AA, et al. Inhibition of human acetylcholinesterase by cyclophosphamide. Toxicology. 1995 Jan 19;96 (1) :1-6.|[3]Harris RN, et al. Carbon tetrachloride-induced increase in the antitumor activity of cyclophosphamide in mice: a pharmacokineticstudy. Cancer Chemother Pharmacol. 1984;12 (3) :167-72.|[4]Liu P, et al. Administration of cyclophosphamide changes the immune profile of tumor-bearing mice. J Immunother. 2010 Jan;33 (1) :53-9.|[5]Dominique A Ramirez, et al. Kinetics of Cyclophosphamide Metabolism in Humans, Dogs, Cats, and Mice and Relationship to Cytotoxic Activity and Pharmacokinetics. Drug Metab Dispos. 2019, 47, 3.|[6]H. Roness, et al. Pharmacological administration of recombinant human AMH rescues ovarian reserve and preserves fertility in a mouse model of chemotherapy, without interfering with anti-tumoural effects. J Assist Reprod Genet. 2019, 36, 9.|[7]Susana Salva, et al. Probiotic Lactobacillus strains protect against myelosuppression and immunosuppression in cyclophosphamide-treated mice. Int Immunopharmacol. 2014, 22, 1.

ACS Appl Bio Mater. 2023 Oct 16;6 (10) :4413-4420.|ACS Nano. 2025 Feb 4;19 (4) :4672-4683.|Apoptosis. 2025 Jun;30 (5-6) :1331-1350.|Biochem Pharmacol. 2021 Jan:183:114340.|Biology (Basel) . 2025 Jul 8;14 (7) :829.|Biomed Res Int. 2022 Jul 13:2022:8495159.|bioRxiv. 2023 Feb 27:2023.02.27.530263.|bioRxiv. 2025 Sep 21.|Biotechnol Appl Biochem. 2025 Jun 18.|BJOG. 2025 Apr:132 Suppl 2:107-119.|Breast Cancer Res Treat. 2023 Jul;200 (2) :193-201.|Cell Death Dis. 2020 Nov 12;11 (11) :976.|Cell Mol Biol Lett. 2025 Feb 19;30 (1) :21.|Cell Rep Med. 2024 Nov 25:101837.|Cell Rep Med. 2025 Apr 2:102053.|Cell Rep. 2025 Mar 25;44 (4) :115466.|Cell Rep. 2025 Sep 2;44 (9) :116215.|Clin Transl Med. 2025 May;15 (5) :e70336.|Cytotechnology. 2025 Apr;77 (2) :76.|Eur J Pharm Sci. 2024 Jul 21:106860.|Evid Based Complement Alternat Med. 2021 Nov 11;2021:1718709.|Evid Based Complement Alternat Med. 2022 Feb 15;2022:7889199.|Exp Ther Med. 2025 Sep 18;30 (6) :224.|Free Radic Biol Med. 2024 Aug 5:S0891-5849 (24) 00589-6.|Heliyon. 2024 Aug 22;10 (17) :e36664.|Int J Biol Macromol. 2024 Jul 26:134195.|Int J Biol Macromol. 2025 Apr 17;310 (Pt 1) :143312.|Int J Mol Sci. 2023 Feb 14;24 (4) :3818.|J Clin Invest. 2024 Mar 7;134 (10) :e172716.|J Ethnopharmacol. 2025 Jul 14;353 (Pt A) :120294.|J Med Chem. 2025 Mar 27;68 (6) :6339-6360.|J Med Food. 2022 Jul;25 (7) :722-731.|J Mol Med (Berl) . 2019 Aug;97 (8) :1183-1193.|J Ovarian Res. 2024 Jan 15;17 (1) :18.|Journal of Dermatologic Science and Cosmetic Technology. 2025 Jun.|Life Sci. 2020 Aug 1;254:117590.|Mol Biol Cell. 2023 May 1;34 (5) :ar47.|Nat Commun. 2021 Jan 4;12 (1) :20.|Nat Commun. 2023 Apr 13;14 (1) :2109.|Oncol Res. 2024 May 23;32 (6) :1109-1118.|Open Life Sci. 2023 Jan 10;18 (1) :20220535.|Patent. US20250228895A1.|Pediatr Res. 2025 Feb 20.|Phys Med Biol. 2020 Sep 24;65 (19) :195004.|Phytomedicine. 2025 Jun 20:145:156996.|Phytomedicine. 2025 Nov 29:150:157633.|Pulm Pharmacol Ther. 2023 Jun:80:102202.|Reprod Sci. 2025 Aug 11.|Saudi J Biol Sci. 2023 Aug;30 (8) :103707.|SSRN. 2025 Feb 18.|SSRN. 2025 Oct 30.|Stem Cell Res Ther. 2025 Aug 26;16 (1) :459.|Toxicol Rep. 2025 Sep 9;15:102125.|Cell Biol Int. 2025 May 22.|J Mol Med (Berl) . 2019 Aug;97 (8) :1183-1193.|Research Square Preprint. 2023 Jul 10.